Navigation Links
Tumors grow faster without blood-supply promoting molecule
Date:11/10/2008

Dense networks of blood vessels thought to spur cancer's growth could actually hinder rather than promote tumor progression, according to a new study at the University of California, San Diego.

The findings partly explain why drugs designed to treat cancer by strangling its blood supply have been disappointing when used alone and why those treatments are more effective when combined with traditional chemotherapy.

Despite their rapid progression, tumors fed by more normal vascular were also more vulnerable to the effects of standard chemotherapy drugs, the team reports in this week's early online edition of the journal Nature.

Nascent tumors take off as new blood vessels invade, an event called angiogenesis that many see as key to the development of malignancy. But those pathological vessels form tangled structures that are far from normal.

"Tumor blood vessels become more chaotic, disorganized and leaky," said Randall S. Johnson, professor of molecular biology at UC San Diego who led the study. "They become dysfunctional in many ways as a blood vessel network."

Cellular secretions within tumors promote the invasion. The first drugs designed to curtail cancer's blood supply targeted one of these, called VEGF for vascular endothelial growth factor. Inflammatory cells, which infiltrate many types of tumors, provide one source of VEGF.

Johnson's team created a strain of mice in which most inflammatory cells were missing the gene for VEGF, then cross-bred them with a strain that reliably develops mammary tumors and is commonly used to study breast cancer.

"The blood vessels look more organized and less leaky in the engineered mice," said Christian Stockmann, a molecular biology postdoctoral fellow and the first author of the paper.

The blood supply to tumors in these mice was also sparse compared to mice with intact VEGF genes.

"A lot of these classic hallmarks of tumor blood vessels disappeared when the inflammatory cells couldn't make VEGF," Johnson said.

But the cancer grew faster.

All of the mice developed tumors, but at 20 weeks of age, those with low levels of VEGF from inflammatory cells had larger growths that were more likely to have progressed to a later stage of cancer.

"The tumors seemed much happier when they didn't have this chaotic vasculature," Johnson said.

The scientists also injected a cancerous cell line into normal and engineered mice and found that the introduced cells invaded normal tissues more readily without VEGF from inflammatory cells and developed more normal blood supplies.

The tumors that formed were also more susceptible to two different chemotherapy drugs in the mice lacking VEGF from inflammatory cells.

By identifying the cellular source of the critical factor for one pathology associated with cancer, the researchers say their findings may open new avenues for treatment.


'/>"/>

Contact: Randall Johnson
rsjohnson@ucsd.edu
858-822-0509
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Researchers identify mechanism, possible drug treatment for tumors in neurofibromatosis
2. Chemo Alone Effective in Treating Kids Brain Tumors
3. Breast Cancer Vaccine Blasts Some Tumors
4. Nanomedical approach targets multiple cancer genes, shrinks tumors more effectively
5. Drug Re-Sensitizes Breast Tumors to Treatment
6. Drug/radiation combo may help shrink established tumors
7. Leading Neurosurgical Center in Moscow Purchases CyberKnife System to Expand Ability to Treat Brain and Spinal Tumors
8. Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study
9. Researchers hone technique to KO pediatric brain tumors
10. Researchers identify promising cancer drug target in prostate tumors
11. Identification of 5 genes involved in the metastasis of breast tumors to the lung
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... Four Circles Recovery Center, a leading treatment center ... announce the launch of its new extended care program, Fifth Circle. Available for clients ... Circles or another primary treatment program, Fifth Circle is designed to foster the recovery ...
(Date:5/23/2016)... ... 23, 2016 , ... Bio-Optronics, Inc. is delighted to announce ... its recent and anticipated growth. , Max Elbaz was appointed as Vice President, ... segments. Max joined the Bio-Optronics team in March. His areas of expertise include ...
(Date:5/23/2016)... Plano, TX (PRWEB) , ... May 23, 2016 , ... ... Analytics’ on June 10, 2016 from 11:00 AM – 12:00 PM ET. To ... GlobalHealth’s decision to start a proactive outreach program built on Big Data with a ...
(Date:5/23/2016)... ... , ... Celebrating their 20th anniversary this year, Metcal Technologies ... MadgeTech data loggers. These qualifications translate to excellent customer service for the life ... and valued distributors. , Metcal is now offering the RFC1000 Cloud Relay ...
(Date:5/23/2016)... ... ... announced today the upcoming airing of Innovations with Ed ... 2016 at 4:00pET via Fox Business. , The show ... innovation to safely and rapidly develop cures for mosquito-borne, ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... , May 23, 2016   Purdue ... entered into an agreement with Egalet Corporation and ... claims. As part of the agreement the companies ... will enable all three companies to develop and ... "This agreement reflects the commitment of ...
(Date:5/20/2016)... 20, 2016 ReportsnReports.com adds ... Medical Devices of its online business intelligence library. ... the current state of the Titrator industry. The ... like definitions, classifications, Specifications, applications and industry chain ... like Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost ...
(Date:5/20/2016)... LONDON , May 20, 2016 ... for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant ... Emerging Biological Drugs - This New Study Reveals ... Stay Ahead ,What is the ... get the latest technological and commercial analysis. Staying ...
Breaking Medicine Technology: